Prostate Cancer

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth J. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tseo, Nicole A. Schreiber, Glenn Heller, Howard I. Scher

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; University of Minnesota Medical School, Minneapolis, MN, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; NorthShore University HealthSystem, Evanston, IL, USA; Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA; University of Michigan, Ann Arbor, MI, USA; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; New York University, New York, NY, USA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA; Urology Cancer Center and GU Research Network, Omaha, NE, USA; Columbia University, New York, NY, USA; Convergent Therapeutics, New York, NY, USA; Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Prostate Cancer Clinical Trials Consortium, New York, NY, USA

Abstract

Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus prednisone (AAP) in BCR is unknown.

Objective: To compare the rates of complete biochemical responses after testosterone recovery after 8 mo of AAP and degarelix, a gonadotropin-releasing hormone antagonist, alone or in combination.

Design, setting, and participants: Patients with BCR (prostate-specific antigen [PSA] ≥1.0 ng/ml, PSA doubling time ≤9 mo, no metastases on standard imaging, and testosterone ≥150 ng/dl) after prostatectomy (with or without prior radiotherapy) were included in this study.

Intervention: Patients were randomized to AAP (arm 1), AAP with degarelix (arm 2), or degarelix (arm 3) for 8 mo, and monitored for 18 mo.

Outcome measurements and statistical analysis: The primary endpoint was undetectable PSA with testosterone >150 ng/dl at 18 mo. Secondary endpoints were undetectable PSA at 8 mo and time to testosterone recovery.

* Corresponding author.
E-mail address: autiok@mskcc.org (K.A. Autio).

https://doi.org/10.1016/j.euros.2021.09.015
2666-1683/© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The transformative and practice-changing trials in prostate cancer, first in metastatic castration-resistant prostate cancer and later in noncastrate or hormone-sensitive metastatic disease, used time-to-event endpoints that required large numbers of patients and years of follow-up [1,2]. Now that multiple effective therapies are available—with even more in development—there are numerous potential combinations. Given the long natural history of biochemical recurrence (BCR) after prostatectomy, there is a need for response-based endpoints that occur early rather than time-to-event endpoints that occur late when evaluating new therapies in this population so that only the most promising ones are selected for more definitive study.

To address this, we employed a novel response endpoint—undetectable levels of prostate-specific antigen (PSA) with testosterone recovery—to assess the potential elimination of disease in patients with high-risk biochemically recurrent, nonmetastatic prostate cancer. While more men who received the combination had an undetectable prostate-specific antigen (PSA) level at 8 mo on treatment, once men came off treatment and testosterone level rose, there was no difference in the rates of undetectable PSA levels. This suggests that the combination is not able to eradicate disease any better than ADT alone.

Results and limitations: For the 122 patients enrolled, no difference was found between treatments for the primary endpoint (arm 1: 5.1% [95% confidence interval (CI): 1–17%], arm 2: 17.1% [95% CI: 7–32%], arm 3: 11.9% [95% CI: 4–26%]; arm 1 vs 2, p = 0.93; arm 2 vs 3, p = 0.36). AAP therapy showed the shortest median time to testosterone recovery (36.0 wk [95% CI: 35.9–36.1]) relative to degarelix (52.9 wk [95% CI: 49.0–56.0], p < 0.001). Rates of undetectable PSA at 8 mo differed between AAP with degarelix and degarelix alone (p = 0.04), but not between AAP alone and degarelix alone (p = 0.12). Limitations of this study include a lack of long-term follow-up.

Conclusions: Rates of undetectable PSA levels with testosterone recovery were similar between arms, suggesting that increased androgen suppression with AAP and androgen deprivation therapy (ADT) is unlikely to eradicate recurrent disease compared with ADT alone.

Patient summary: We evaluated the use of abiraterone acetate plus prednisone (AAP) and androgen deprivation therapy (ADT), AAP alone, or ADT alone in men with biochemically recurrent, nonmetastatic prostate cancer. While more men who received the combination had an undetectable prostate-specific antigen (PSA) level at 8 mo on treatment, once men came off treatment and testosterone level rose, there was no difference in the rates of undetectable PSA levels. This suggests that the combination is not able to eradicate disease any better than ADT alone.

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
recognizing the inherent difficulties associated with MFS and overall survival (OS) endpoints, which can be affected by subsequent therapy and require many years of follow-up. To circumvent these challenges, patients were randomized and treated for 8 mo with either AAP or degarelix, or the combination, and as a benchmark for success for this trial, we selected a binary endpoint of an undetectable serum PSA level with testosterone recovery at 18 mo from treatment initiation. Achieving this endpoint would not be definitive; however, it would support moving this combination forward into larger, definitive trials [3].

2. Patients and methods

This randomized phase 2 trial (ClinicalTrials.gov identifier: NCT01751451) was conducted at Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Weill Cornell Medicine, Rutgers Cancer Institute of New Jersey, Karmanos Cancer Institute, University of North Carolina at Chapel Hill, Duke University, Oregon Health & Science University, New York University, NorthShore University HealthSystem, and Urology Cancer Center and GU Research Network. The protocol was approved by the respective institutional review boards; all patients signed a study-specific informed consent form.

2.1. Patients

All patients had undergone a radical prostatectomy (RP) for localized prostate cancer and had experienced a biochemical (ie, PSA) recurrence. All had rising serum PSA levels based on at least three time points taken at least 1 wk apart, with a minimum PSA level of 1 ng/ml. PSA doubling time at the time of trial entry was <9 mo. A testosterone level of at least 150 ng/dl was required. CT or MRI and bone scan were performed to exclude those with metastatic disease, although pelvic or retroperitoneal lymph nodes smaller than 2 cm in short axis were allowed. Prior salvage radiation therapy and ADT of <8 mo of duration in the neoadjuvant or radiation therapy setting were allowed. Required laboratory values included hemoglobin >9 g/dl, platelets 100 000 mm\(^3\), creatinine ≤1.5 mg/dl, and alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/total bilirubin ≤1.5 upper limit of normal. Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic pressure ≥95 mmHg, was exclusionary. Concomitant medications including CYP2D6 substrates and CYP3A4 inducers were not permitted. Prior ketoconazole, abiraterone acetate, and enzalutamide were not included in exploratory and secondary analyses. The protocol provided guidance for dose holding and dose reductions for hepatotoxicity, hypertension, and pulmonary edema/anasarca. Serious adverse events were provided to the sponsor (Memorial Sloan Kettering Cancer Center, the lead site) and Janssen Scientific Affairs; local institutional review board notification occurred via standard site regulations.

The primary endpoint was undetectable PSA with testosterone >150 ng/dl, measured at 18 mo from the start of treatment. Secondary endpoints included the percentage of patients with undetectable PSA at 8 mo, adverse events, and testosterone recovery rates. A post hoc exploratory analysis was performed to assess PSA progression-free survival (PFS).

2.2. Study design

Patients were randomized in an open-label fashion 1:1:1 to receive AAP, AAP with degarelix, or degarelix alone (Fig. 1). Abiraterone acetate was administered orally as a fasting medication at 1000 mg daily, with prednisone 5 mg orally twice a day. A subcutaneous injection of degarelix 80 mg was given monthly after an initial loading dose of 240 mg. Treatment lasted for 8 mo, then patients entered follow-up and were seen monthly for toxicity assessments, serum PSA, and testosterone levels for up to 18 mo. If patients developed a confirmed rise in PSA (defined as a 25% rise above nadir) during the treatment period, they were taken off study for disease progression. During follow-up, patients were taken off study for disease progression if their PSA was detectable and confirmed detectable at a second time point. All laboratory tests were assessed locally. Five sites used an assay with a lower limit of detection of <0.06, and six sites’ assay used a lower limit of detection of 0.10.

2.3. Statistical analysis

A total of 120 patients were planned for the three treatment groups. Each AAP group (monotherapy and in combination with degarelix) was compared with the degarelix-alone arm. With 40 patients per group, it was assumed that the probability of success in the degarelix-only group was ≤0.25 and the probability of success was at least 0.20 greater than degarelix alone in the AAP-based groups. Under these projections, there was a >80% chance of finding for either AAP-based treatment relative to degarelix alone using a Fisher’s exact test with a one-sided 0.20 significance level. The choice of a 0.20 significance level was intended to reduce the sample size required for this comparative trial. Owing to the high risk of a type I error, a significant outcome would not imply definitive evidence of superiority for either AAP-based treatment relative to degarelix alone; however, it would provide sufficient evidence that testing of AAP should proceed.

Fisher’s exact test was utilized to compare each AAP group (monotherapy or in combination with degarelix) relative to degarelix alone for the primary and secondary efficacy endpoints. In an exploratory analysis, the Kaplan-Meier estimate was used to compute PSA PFS estimates, and the cumulative incidence function was applied to estimate the probability of testosterone recovery over time. The logrank test and Gray’s test were used, respectively, to compare these endpoints across treatment arms. Fisher’s exact and Wilcoxon rank sum tests were conducted to assess for associations between select clinical factors (age, prior ADT, prior salvage radiation therapy, tumor stage at RP, and time from RP to study entry) and the primary endpoint.

3. Results

3.1. Patients

A total of 122 patients were randomized 1:1:1 to receive AAP, AAP with degarelix, or degarelix alone; 120 received at least one dose of study drug. Ten patients with undetectable PSA at 18 mo had not recovered testosterone, so their treatment was considered a failure. The intent-to-treat population (n = 122) was used to evaluate the primary endpoint, and the two patients who were not treated were not included in exploratory and secondary analyses.

The median age of the patients was 65 yr (range, 43–83 yr), and 43% (53/122) had Gleason ≥8 disease (Table 1). Of the patients, 57% (70/122) had pT3 or pT4 disease, and 61% (74/122) had received salvage radiotherapy. The median PSA level at trial entry was 4.4 ng/ml (range, 1.0–48.3 ng/ml).

3.2. Safety

Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [23]. The
122 Patients enrolled

Arm 1: AAP
(n = 39 randomized; 37 treated)

Arm 2: AAP + D
(n = 41 randomized and treated)

Arm 3: D
(n = 42 randomized and treated)

Fig. 1 – CONSORT diagram. AAP = abiraterone acetate plus prednisone; D = degarelix.

Table 1 – Patient characteristics.

| Baseline characteristics | Arm 1: AAP (n = 39) | Arm 2: AAP + D (n = 41) | Arm 3: D (n = 42) | All cohorts (n = 122) |
|--------------------------|---------------------|-------------------------|------------------|---------------------|
| Age (yr)                 | 64 (43–83)          | 65 (51–74)              | 66 (46–78)       | 65 (43–83)          |
| Race                     |                     |                         |                  |                     |
| Black or African American| 4 (10)              | 6 (15)                  | 3 (7)            | 13 (11)             |
| White                    | 35 (90)             | 33 (80)                 | 39 (93)          | 107 (88)            |
| Unknown                  | 0 (0)               | 2 (5)                   | 0 (0)            | 2 (1)               |
| PSA (ng/ml)              | 3.1 (1.2–35.4)      | 5.8 (12–45.1)           | 4.1 (1.0–48.3)   | 4.4 (1.0–48.3)      |
| Testosterone ng/dl       | 352 (162–739)       | 318 (176–841)           | 355.5 (151–904)  | 331 (151–904)       |
| Albumin (g/dl)           | 4.3 (3.3–4.8)       | 4.3 (3.5–5.0)           | 4.3 (3.4-4.9)    | 4.3 (3.3–5.0)       |
| Alkaline phosphatase (units/l) | 66 (29–134)      | 66 (36–111)             | 70 (42–139)      | 67 (29–134)         |
| LDH (units/l)            | 170 (96–554)        | 170 (135–459)           | 173 (121–539)    | 170 (96–554)        |
| Hemoglobin (g/dl)        | 14.3 (12.3–18.9)    | 14.3 (11.9–16.6)        | 14.2 (12.4–17.2) | 14.3 (11.9–18.9)    |
| ECOG performance status  |                     |                         |                  |                     |
| 1                        | 4 (10)              | 2 (5)                   | 3 (7)            | 9 (7)               |
| 0                        | 35 (90)             | 39 (95)                 | 39 (93)          | 113 (93)            |
| Prostatectomy Gleason score |                 |                         |                  |                     |
| Unknown                  | 2 (5.1)             | –                       | –                | 2 (1.6)             |
| Total Gleason score 6 or 7| 20 (51.3)          | 22 (53.7)               | 25 (59.5)        | 67 (54.9)           |
| Total Gleason score ≥8   | 17 (43.6)           | 19 (46.3)               | 17 (40.5)        | 53 (43.4)           |
| TNM stage                |                     |                         |                  |                     |
| Unknown                  | 2 (5)               | 1 (2)                   | 2 (5)            | 5 (4)               |
| pT1a-pT2 N0 or NX        | 8 (21)              | 21 (51)                 | 18 (43)          | 47 (39)             |
| pT3a N0 or NX            | 13 (33)             | 11 (27)                 | 9 (21)           | 33 (27)             |
| pT3a N1                  | 2 (5)               | 0 (0)                   | 1 (2)            | 3 (2)               |
| pT3b N0 or NX            | 10 (26)             | 6 (15)                  | 10 (34)          | 26 (21)             |
| pT3b N1                  | 3 (8)               | 2 (5)                   | 2 (5)            | 7 (6)               |
| pT4 NX                   | 1 (3)               | 0 (0)                   | 0 (0)            | 1 (1)               |
| Prior therapies          |                     |                         |                  |                     |
| Salvage radiation therapy | 23 (59)            | 24 (59)                 | 27 (64)          | 74 (61)             |

AAP = abiraterone acetate plus prednisone; D = degarelix; ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase; PSA = prostate-specific antigen; TNM = tumor node metastasis.

Data are given as n (%) or median (range).
most common toxicities across all three arms were hot flashes (77%) and fatigue (51%; Table 2). Elevations in AST or ALT of any grade occurred in 15–16% of patients overall. In the AAP arms, 2–3% of patients experienced a grade 3 increase in AST and 5% experienced a grade 3 increase in ALT. Hypertension of any grade was identified in 19%, 20%, and 7% of patients in the AAP, AAP with degarelix, and degarelix arms, respectively. Ten patients experienced dose interruptions due to adverse events. Three patients had dose reductions of AAP. One patient discontinued because of transaminitis.

### 3.3. Efficacy

The primary endpoint, undetectable PSA with testosterone recovery at 18 mo, was achieved in 5.1% (95% CI: 1–17%) of patients in the AAP arm, 17.1% (95% CI: 7–32%) in the AAP with degarelix arm, and 11.9% (95% CI: 4–26%) in the degarelix-only arm (Table 3). No difference was found in either AAP arm relative to degarelix (arm 1 vs 3, \( p = 0.93 \); arm 2 vs 3, \( p = 0.36 \)). Ten patients had an undetectable PSA level at 18 mo, but had not recovered testosterone, and two were never treated. Sensitivity analyses were performed, and whether these patients are included as meeting the endpoint, not meeting the endpoint, or excluded from the analysis did not change the overall primary endpoint results (Supplementary Table 1).

Secondary endpoints included the percentage of patients who achieved an undetectable PSA level at 8 mo, which was highest in the AAP with degarelix arm (87.8%) and lowest with degarelix alone (66.7%), and was achieved in 83.8% of patients treated with AAP alone (Table 3). The rate of undetectable PSA levels at 8 mo differed between AAP with degarelix and degarelix-alone arms (\( p = 0.04 \)), but not between AAP-alone and degarelix-alone arms (\( p = 0.12 \)). Among patients who recovered their testosterone within 18 mo, the time to PSA progression was longest in the AAP with degarelix arm (median 64.4 wk, 95% CI: 57.9–NA), and shortest in those receiving AAP alone (median 37.5 wk, 95% CI: 36.3–44.0); the degarelix-alone arm experienced PSA progression at a median of 54.9 wk (95% CI: 47.9–60.7; Fig. 2A). The median time from the start of treatment to testosterone recovery was 56 wk (95% CI: 54.9–60.7) in the combination arm, 52.9 wk (95% CI: 49.0–56.0) with degarelix, and 36 wk (95% CI: 35.9–36.1) in the AAP arm (Fig. 2B). The AAP-alone arm had a more rapid testosterone recovery than either degarelix arm (\( p < 0.001 \)).

### Table 2 – Treatment-related adverse events.

| Adverse event | ARM 1: AAP (n = 37) | ARM 2: AAP + D (n = 41) | ARM 3: D (n = 42) | All cohorts (N = 120) |
|---------------|---------------------|-------------------------|-------------------|----------------------|
|               | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Grade 1 | Grade 2 | Grade 3 | Any grade |
| Hot flashes   | 21 (57) | 1 (3)  | –      | 28 (68) | 5 (12)  | –      | 35 (83) | 2 (5)  | –      | 92 (77)  |
| Fatigue       | 16 (43) | 1 (3)  | –      | 16 (39) | 2 (5)   | –      | 24 (57) | 1 (2)  | 1 (2)  | 61 (51)  |
| Injection site reaction | –      | –      | 9 (22) | 1 (2)   | –      | 9 (21)  | –      | –      | 19 (16) |
| ALT increased | 4 (11)  | 2 (5)  | 2 (5)  | 3 (7)   | 2 (5)   | 2 (5)  | 4 (10) | –      | –      | 19 (16) |
| Hypertension  | 2 (5)   | 4 (11) | 1 (3)  | 2 (5)   | 4 (10)  | 2 (5)  | 1 (2)  | 1 (2)  | 1 (2)  | 18 (15) |
| AST increased | 7 (19)  | 1 (3)  | 1 (3)  | 4 (10)  | 1 (2)   | 1 (2)  | 3 (7)  | –      | –      | 18 (15) |
| Insomnia      | 5 (14)  | 1 (3)  | –      | 3 (7)   | –      | –      | 6 (14) | 1 (2)  | –      | 16 (13) |
| Depression    | 2 (5)   | –      | –      | 2 (5)   | 1 (2)   | –      | 3 (7)  | 2 (5)  | –      | 10 (8)  |
| Nausea        | 4 (11)  | –      | –      | 4 (10)  | –      | –      | –      | –      | –      | 8 (7)    |
| Hyperglycemia | 1 (3)   | –      | 1 (2)  | 1 (2)   | 2 (5)   | –      | 1 (2)  | 1 (2)  | 1 (2)  | 7 (6)    |
| Breast pain   | 5 (14)  | 2 (5)  | –      | –      | –      | –      | –      | –      | –      | 7 (6)    |
| Urinary frequency | 3 (8)  | 1 (3)  | –      | –      | 1 (2)   | –      | 1 (2)  | –      | –      | 6 (5)    |
| Anemia        | 1 (3)   | –      | 1 (3)  | 1 (2)   | –      | –      | 3 (7)  | –      | –      | 6 (5)    |
| Gynecomastia  | 4 (11)  | –      | –      | 1 (2)   | –      | –      | 1 (2)  | –      | –      | 6 (5)    |
| Headache      | 2 (5)   | 1 (3)  | –      | 2 (5)   | –      | –      | 1 (2)  | –      | –      | 6 (5)    |

AAP = abiraterone acetate plus prednisone; ALT = alanine aminotransferase; AST = aspartate transaminase; CTCAE = Common Terminology Criteria for Adverse Events; D = degarelix.

Data are presented as \( n \) (%).

### Table 3 – Efficacy as measured by PSA.

| Treatment | Secondary endpoint: undetectable PSA at 8 mo (n = 120) | Median time to testosterone recovery a (n = 120) | Primary endpoint: undetectable PSA at 18 mo with testosterone recovery (n = 122) |
|-----------|------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------------|
| Arm 1:    | 31 (83.8)                                            | 36 wk                                            | 2 (5.1)                                                                      |
| Arm 2:    | 36 (87.8)                                            | 56 wk                                            | 7 (17.1)                                                                      |
| Arm 3:    | 28 (66.7)                                            | 53 wk                                            | 5 (11.9)                                                                      |

PSA = prostate-specific antigen.

Data are presented as \( n \) (%).

a Time to testosterone recovery was calculated from treatment start.
median age 69.5 vs 64.0 yr; \( p = 0.004 \) and have had prior salvage radiation (79% vs 47%; \( p = 0.04 \)), with a longer time between RP and starting on trial (median time 270 vs 175 d; \( p = 0.06 \)). There was no association between meeting the primary endpoint and prior ADT or tumor stage at the time of RP.

Data are available for bona fide researchers who request it from the authors.

4. Discussion

The more complete androgen suppression resulting from the combination of AAP and degarelix enabled 17.1% (95% CI: 7–32%) of patients with BCR to achieve an undetectable PSA level after testosterone recovery. However, this effect did not differ between treatment arms, and 11.9% (95% CI: 4–26%) of patients who received ADT alone achieved a similar outcome. In an exploratory analysis, PSA PFS was longest with combination therapy, which may in part be attributable to the longer time to testosterone recovery. The group with the shortest PSA PFS was the AAP arm that experienced testosterone recovery approximately 4–5 mo earlier than patients in the other arms. Additionally, although the PSA PFS curves separate, the difference in time to PSA PFS between the degarelix arm (median 54.9 wk, 95% CI: 47.9–60.7) and the AAP and degarelix combination arm (median 64.4 wk, 95% CI: 57.9–NA) was 10 wk, which is arguably not clinically meaningful.

The primary endpoint of the trial—undetectable PSA with testosterone recovery at 18 mo—was utilized to address the recognized need for earlier readouts of efficacy, shifting from late time-to-event-progression endpoints to earlier response endpoints based on the principles outlined by the Prostate Cancer Working Group 3 [24]. This endpoint will require more extensive study and is not a surrogate for survival; however, given the long natural history of this disease and the biologic rationale as a tumor driven by androgens, we felt it appropriate for use in this phase 2 setting [8]. A contemporary study in the phase 2 setting of salvage radiotherapy utilized a fixed course of ADT with enzalutamide and employed a 2-yr PSA PFS endpoint with expectations of testosterone recovery at that time point [25]; although the treatment and population differ from our trial, this study also utilized detectable PSA as a near-term endpoint after testosterone recovery [25]. For comparison, the pivotal phase 3 trial using a survival endpoint in high-risk biochemically recurrent disease initiated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) randomized 1386 men to intermittent versus continuous ADT and took nearly 14 yr to conduct [26]. Between 2003 and 2020, ten drugs were approved by the Food and Drug Administration for the treatment of castration-resistant prostate cancer; many of these are now being used or evaluated for use in earlier disease states. With more agents and combinations available for testing, the demand for efficient phase 2 trial design has increased. New life-prolonging therapies that can be administered upon progression on a clinical trial can also blunt OS outcomes.

In the contemporary setting of androgen receptor inhibitors, the EMBARK trial (NCT02319837) is enrolling 1860 patients with BCR across 200 international sites and evaluating the continuous use of ADT alone, enzalutamide alone, and enzalutamide in combination with ADT, and uses a primary endpoint of MFS. Another trial in BCR, AFT-19 (NCT03009981), will randomize 504 patients to ADT alone, ADT with apalutamide and AAP, and ADT with apalutamide for 12 mo. This trial will use a primary endpoint of PSA PFS,
with MFS as a secondary endpoint. Smaller phase 2 trials such as the one reported here (122 patients) are not intended to be definitive trials; rather these utilize an economical design and response endpoint to help inform decisions for the development of these larger-scale, costly studies with long maturity times.

Despite the modest sample size, this study took longer to complete than anticipated, with 5 yr elapsing between the trial opening and data cutoff. A primary reason was prolonged accrual time due to difficulty in identifying high-risk patients. Opening additional study sites might have helped mitigate. A limitation of this trial is a lack of long-term follow-up, so the durability of PSA response and time to subsequent treatment, as well as whether this endpoint predicts for MFS or OS, are unknown. Patients who met the primary endpoint were older, and more likely to have had prior salvage radiation therapy, than those who did not meet the primary endpoint, but the sample size is too small to draw firm conclusions.

It should be noted that our understanding and characterization of biochemically recurrent disease, previously defined by conventional bone scan and CT/MRI, are changing with advances in positron emission tomography (PET) imaging such as Ga-68-labeled Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68 (HBED-CC)] prostate-specific membrane antigen (PSMA) PET/CT and 18F-fluciclovine PET/CT [27–31]. While it is recognized that patients with BCR likely harbor micrometastases, this becomes more obvious with greater imaging sensitivity and provides opportunities for trial designs. Contemporary phase 2 trials may enroll PSMA-positive/ conventional scan–negative (negative for metastatic disease) patients alongside PSMA-negative/conventional scan–negative patients provided that the endpoint, such as the one utilized in this trial, captures both populations [6].

5. Conclusions

Although the primary endpoint did not differ between treatment arms, the knowledge that 12% of men achieved an undetectable PSA level after testosterone recovery with standard ADT sets a benchmark for future trials. Further study of this endpoint as it relates to OS and MFS will be necessary. Our understanding of intratumoral androgens, genomic alterations, and alternative pathways, coupled with advances in drug development, has the potential to transform the management of BCR. Efficient phase 2 trial designs with meaningful response measures will enable drug development to keep abreast of the science.

Financial disclosures: Karen A. Autio certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Antonarakis: consultant and honorarium recipient—Amgen, Astellas, AstraZeneca, Clovis, Dendreon, Eli Lilly and co., ESA, Janssen, Medivation, and Sanofi; consultant without honorarium—Bayer; research funding to institution—AstraZeneca, BMS, Celgene, Clovis, Dendreon, Genetech, Janssen, Merck, Novartis, Sanofi, and Tokai; patent holder/licensor: Qiagen. Apollo: no disclosures. Armstrong: research funding to institution—Janssen, Pfizer/Astellas, BMS, Merck, AstraZeneca, Genentech/Roche, Forma, Celgene, Amgen, Beigene, Constellation, Bayer, and Dendreon; consulting—Janssen, Pfizer, Astellas, BMS, Merck, AstraZeneca, Bayer, Dendreon, and Forma. Auto: research funding to institution—CytomX, AstraZeneca, Pfizer, Amgen, GlaxoSmithKline, Parker Institute for Cancer Immunotherapy, and Trishula. Balar: consultant/advisory role—Incyte, BMS, Janssen, Merck, Pfizer, Astra Zeneca, Nektar, Seagen, and Immunogenics/Gilead; research funding to institution—Genetech, Merck, AstraZeneca, Nektar, Seagen, and Immunogenics/Gilead; equity—EpiVax Oncology. Beer: stock and other ownership interests—Arvinas and Sutarius Pharmaceuticals; consulting or advisory role—Astellas, Arvinas, AstraZeneca, Bayer, BMS, Clovis, Constellation Pharmaceuticals, GRAIL, Janssen, Novartis, Pfizer, Sanofi, Tolero, and Myovant Sciences; research funding to institution—Alliance Foundation Trials, Astellas, Boehringer Ingelheim, Corcept Therapeutics, Endocyte, Freenome, GRAIL, Harpoon Therapeutics, Janssen, Medivation, Sotio, OraGene, Genentech, and Genmab; research funding to institution—Genentech, Merck, AstraZeneca, Nektar, Seagen, and Immunogenics/Gilead; equity—EpiVax Oncology. Bhatia: no disclosures. George: consultant—Astellas, AstraZeneca, Bayer, BMS, Constellation Pharmaceuticals, Exelixis, Flatiron, Janssen, Merck Sharp and Dohme, Michael J Hennessey Associates, Myovant Sciences Inc., Physician Educational Research LLC, Pfizer, Propella TX, RxHealth, and Sanofi; research funding to institution—Astellas, AstraZeneca, BMS, Calithera, Exelixis, Janssen, Novartis, Pfizer, and Sanofi; advisory board—Astellas, AstraZeneca, Capio Biosciences, Modra Pharmaceuticals BV, UroGPO, and UroToday; honorarium—Bayer, EMD Serono, Exelixis, Ipsen, Michael J Hennessey Associates, and Sanofi; speaker—Bayer, Exelixis, Pfizer, and Sanofi; travel—Bayer, Exelixis, UroToday, and Sanofi; Gruff: research funding to institution—Merck, Sanofi, Astellas/Pfizer, and Janssen. Harrison: research funding to institution—Acerta, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Clovis Oncology, Merck, Pfizer, and Seattle Genetics; consulting—AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Fujifilm, Genentech, Immunogenics, Janssen, Pfizer, and Seattle Genetics; promotional speaking—Exelixis and Genentech. Heath: honoraria—Bayer,
Sanofi, and Seattle Genetics; consulting/advisory role—Astellas; advisory board—Astra Zeneca, BMS, and Sanofi; paid travel—Astellas, Caris Life Sciences, Sanofi, and Seattle Genetics; research funding to institution—Astellas Pharma, AstraZeneca, Boehringer Ingelheim, BMS, Caris Life Sciences, Celgene, Celldex, Corcept, Curemeta, Dendreon, effECTOR Therapeutics, Esanik, Fortis Therapeutics, Genetech/Roche, GSK, Ignivo, Inovio Pharmaceuticals, Medivation, Merck Sharp and Dohme, Merck, Millennium, Oncolyx BioPharm, Plexxicon, Seattle Genetics, Synta, Tokai Pharmaceuticals, and Zenith Epigenetics. Heller: no disclosures. Mayer: honoraria—EMD Serono, and Exelixis; consulting—AstraZeneca; research funding to institution—Sotio, Merck, and Pfizer/EMD Serono. Milowsky: research funding to institution—Merck, Roche/Genetech, BMS, Astellas, Clovis, Inovio, Mirata, Constellation Pharmaceuticals, Syndax, Incyte, Amgen, Regeneron, Arvinas, Seagen, Pfizer, Johnson, and Johnson/Janssen. Morris: uncompensated consultant: Advanced; accelerator applications—Johnson and Johnson, and Novartis; consultant (<5K): NCCN, Curium, and Oric; research funding to institution—Bayer, Sanofi, Endooyce, Progenics, Corcept, Roche/Genetech, and Janssen, Nordquist and Paller: no disclosures. Rathkopf: consulting or advisory role (all uncompensated)—Genentech/Roche, Janssen Oncology, AstraZeneca, and Myovant; research funding to institution—AstraZeneca, Celgene, Ferring, Genetech/Roche, Janssen Oncology, Medivation, Millennium, Novartis, Taiho Pharmaceutical, Takeda, TRACON Pharma, and Phosplatin. Scher: compensated Board of Directors’ member—Asterias Biotherapeutics; compensated consultant/advisor—Amybry Genetics Corp, Konica Minolta Inc., Bayer, Pfizer Inc., Sun Pharmaceuticals, and WCG Oncology; uncompensated consultant/advisor—Amgen, ESSA Pharma Inc. Janssen Research & Development, LLC, Janssen Biotech, Inc., and Sanofi Aventis; research funding (to institution)—Epic Sciences, Illumina, Inc., Janssen, Menarini Silicon Biosystems, Prostate Cancer Foundation, and ThermoFisher; intellectual property rights—BioNTech, Elucida Oncology, MaBVAX, and Y-mAbs Therapeutics, Inc.; nonfinancial support—Amgen, Asterias Biotherapeutics, Bayer, ESSA Pharma Inc., Menarini Silicon Biosystems, Phosplatin, Pfizer Inc, Prostate Cancer Foundation, and WCG Oncology. Schreiber: no disclosures. Shevchik: speakers—Sanofi and Bayer. Slovín: honoraria for advisory boards/educational programs—Novartis, Janssen, Pfizer, Merck, Sanofi-Aventis, Clovis, and Physician Education Resource; research funding to institution—Sanofi-Aventis, Novartis, Poseida Pharma, Immunomedex, and Prostate Cancer Foundation. Stein: consulting/advisory role—Merck Sharp and Dohme, Exelixis, Xencor, Janssen, and Oxford Oncology; research funding to institution—Oncoceutics, Merck Sharp and Dohme, Janssen, Mediivation/Astellas, Advaxis, Suzhou Kintor Pharmaceuticals, Harpoon, BMS, Genocoe Biosciences, Lilly, Nektar, Seattle Genetics, Xencor, Tmunity, and Exelixis. Tagawa: honoraria—Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endooyce, Eisai, Immunomedics, Karyophym, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Alkido Pharma, and Gilead Sciences; research funding to institution—Sanofi, Medivation, Astellas, Janssen, Amgen, Genentech, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyophym, Endooyce, Clovis, Seattle Genetics, AAA/Novartis, POINT Biopharma, and Gilead Sciences. Tse: no disclosures. Vaishampayan: research funding to institution—BMS, Exelixis, and Merck; consulting and honoraria—AAA, Alkermes, Bayer, BMS, EMD Serono, Pfizer, Sanofi, Exelixis, and Merck.

**Funding/Support and role of the sponsor** This research was funded in part through an NIH/NCI Cancer Center Support Grant to Memorial Sloan Kettering (P30 CA008748) and Janssen Pharmaceuticals, Inc. Memorial Sloan Kettering authors were supported in part by grants from the NIH/NCI (Cancer Center Support Grant P30 CA008748, the SPORE in Prostate Cancer P50 CA092629) and Congressionally Directed Medical Research Programs (W81XWH-18-2-0060) as well as the Sidney Kimmel Center for Prostate and Urologic Cancers, and David H. Koch through the Prostate Cancer Foundation. Emmanuel S. Antonarakis was partially funded by Department of Defense (Congressionally Directed Medical Research Program) grants W81XWH-13-PRCPR-CCA and W81XWH-16-PRCPR-CRCSA, and by National Institutes of Health (Cancer Center support grant P30 CA06973).

**Acknowledgments**

We thank Margaret McPartland, BA, an independently supported editor at Memorial Sloan Kettering.

Portions of this work were previously presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1–5, 2018.

**Appendix A. Supplementary material**

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.euros.2021.09.015](https://doi.org/10.1016/j.euros.2021.09.015).

**References**

[1] Fizazi K, Scher HI, Molina A, et al. Abiraterone acetae for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–92.

[2] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–48.

[3] Teo MY, O’Shaughnessy MJ, McBride SM, Vargass HA, Scher HI. Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nat Rev Clin Oncol 2018;15:168–82.

[4] Morris MJ, Hilden P, Cleave ME, et al. Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. J Clin Oncol 2015;33:5011.

[5] Abeshouse A, Ahr J, Akhani R, et al. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011–25.

[6] Robinson D, Van Allen E, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–28.

[7] Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017;2017:PO.17.00029.

[8] Scher HI, Eisenberger M, D’Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537–56.

[9] Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007;25:1765–71.

[10] Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11:8669–73.

[11] Antonarakis ES, Feng Z, Trock B, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32–9.

[12] Brockman JA, Alanne S, Vickers AJ, et al. Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol 2015;67:1160–7.

[13] Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early
predictor of relapse or incomplete androgen suppression. Urology 2006;68:834–9.

[14] Mostaghel EA, Cho E, Zhang A, et al. Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin Cancer Res 2017;23:4592–601.

[15] Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217–27.

[16] Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54.

[17] Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653–7.

[18] Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815–25.

[19] Fizazi K, Chi KN. Abiraterone in metastatic prostate cancer. N Engl J Med 2017;377:1697–8.

[20] McKay RR, Montgomery B, Xie W, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 2018;21:364–72.

[21] Taplin M-E, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32:3705–15.

[22] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–60.

[23] NIH. National Cancer Institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.

[24] Scher HI, Morris MJ, Stadler WM. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402–18.

[25] Bitting RL, Healy P, George DJ, et al. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2020.01.005.

[26] Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895–903.

[27] Bashir U, Tree A, Mayer E, et al. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Mol Imaging 2019;46:901–7.

[28] Wu SY, Boreta L, Shinohara K, et al. Impact of staging (68)Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer. Urology 2019;125:154–62.

[29] Andriole GL, Kostakoglu L, Chau A, et al. The impact of positron emission tomography with 18F-fluoride on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol 2019;201:322–31.

[30] Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019;5:856. https://doi.org/10.1001/jamaoncol.2019.0096.

[31] Ceci F, Castellucci P, Graziani T, et al. (68)Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging 2019;46:31–9.